GlassScriptPhysician profile
Heather Lesieur
NPI 1891726972
$2,679.42
in general payments reported to CMS, 2019-2025
24 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,427 · 2022: $375 · 2023: $458 · 2024: $215 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $836.41 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $259.99 | 2021-2025 | Breztri, Farxiga |
| Biohaven Pharmaceuticals, INC. | $236.20 | 2021 | |
| Amarin Pharma, INC. | $216.83 | 2021 | |
| Lilly USA, LLC | $145.69 | 2021-2024 | Jardiance, Emgality, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.62 | 2021-2024 | Xifaxan |
| Pfizer INC. | $98.98 | 2021-2023 | |
| Glaxosmithkline, LLC. | $97.01 | 2021-2024 | Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $87.98 | 2022 | |
| Bausch Health US, LLC | $76.88 | 2021 | |
| Exact Sciences Corporation | $74.09 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.25 | 2021-2023 | Jardiance |
| Eisai INC. | $58.81 | 2021 | |
| Novo Nordisk INC | $57.40 | 2021-2023 | Ozempic, Rybelsus |
| Acerus Pharmaceuticals Corporation | $55.02 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $36.54 | 2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $33.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.29 | 2021 | |
| Verity Pharmaceuticals INC. | $22.14 | 2024 | Tlando |
| Organon LLC | $18.68 | 2025 | Nexplanon |
| Insulet Corporation | $18.26 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.86 | 2022 | |
| Antares Pharma, INC. | $15.35 | 2021 | |
| Astellas Pharma US INC | $15.27 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Lesieur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.